dc.contributor.author | Dizman, Nazlı | |
dc.contributor.author | Arslan, Zeynep Ece | |
dc.contributor.author | Feng, Matthew | |
dc.contributor.author | Pal, Sumanta K. | |
dc.date.accessioned | 2020-07-27T06:22:44Z | |
dc.date.available | 2020-07-27T06:22:44Z | |
dc.date.issued | 2020 | en_US |
dc.identifier.citation | Dizman, N., Arslan, Z. E., Feng, M. ve Pal, S. K. (2020). Sequencing therapies for metastatic renal cell carcinoma. Urologic Clinics of North America, 47(3), 305-318. https://dx.doi.org/10.1016/j.ucl.2020.04.008 | en_US |
dc.identifier.issn | 0094-0143 | |
dc.identifier.issn | 1558-318X | |
dc.identifier.uri | https://dx.doi.org/10.1016/j.ucl.2020.04.008 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/5604 | |
dc.description.abstract | In an era of several therapeutic options available, optimal treatment sequencing is crucial to providing patients the most effective therapy and promoting quality of life. In clear cell renal cell carcinoma, a combination approach with an immunotherapy backbone, such as nivolumab/ipilimumab or axitinib/pembrolizumab, has a key role in the first-line setting. Safety and activity data support the transition to single-agent targeted therapies in the second-line setting. Nivolumab monotherapy possesses clinical and mechanistic rationale as a second-line therapeutic option for patients treated with targeted therapies in the first-line setting. Gene expression models are being generated from large prospective clinical trial data sets. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | WB Saunders Co-Elsevier Inc. | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | Targeted Therapy | en_US |
dc.subject | Immunotherapy | en_US |
dc.subject | Sequencing | en_US |
dc.subject | RCC | en_US |
dc.subject | Kidney Cancer | en_US |
dc.title | Sequencing therapies for metastatic renal cell carcinoma | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Urologic Clinics of North America | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi | en_US |
dc.authorid | 0000-0002-8142-2875 | en_US |
dc.identifier.volume | 47 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 305 | en_US |
dc.identifier.endpage | 318 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1016/j.ucl.2020.04.008 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.identifier.scopusquality | Q2 | en_US |